SA
Sakar Healthcare Ltd (SAKAR)
₹944.80
Mkt cap
₹2,625 Cr
P/E ratio
72.70
P/B
6.47
Div yield
0.00%
ROE
9.99%
ROCE
12.40%
EPS (TTM)
₹13.00
Book value
₹146
52W range
352–1,230
Sector
Healthcare
Price history
Previous close
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products [1]
NSE SAKAR
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−23.18% from high₹945
₹352+168.41% from low₹1,230
Current
₹944.80
Prev close
₹946.50
Day
−0.18%
Price performance
1D
−0.79%
1W
+5.53%
1M
−16.30%
3M
+11.20%
6M
+50.08%
1Y
+158.32%
YTD
+132.39%
Financials
Revenue, profit & margin
P/E ratio
72.7×
SAKAR is 110% above the sector median of 34.6×
SAKAR72.7×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026NSE | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39 | 34 | 37 | 43 | 41 | 43 | 43 | 50 | 53 | 58 | 70 | 71 | 73 | 87 | |
| Expenses | 30 | 25 | 28 | 32 | 30 | 31 | 32 | 35 | 40 | 46 | 52 | 45 | 52 | 63 | |
| Operating Profit | 9 | 9 | 9 | 11 | 11 | 12 | 12 | 16 | 13 | 11 | 19 | 26 | 21 | 24 | |
| OPM % | 23% | 27% | 24% | 25% | 26% | 27% | 27% | 31% | 24% | 20% | 26% | 37% | 29% | 28% | |
| Other Income | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | |
| Interest | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | |
| Depreciation | 5 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | |
| Profit before tax | 4 | 4 | 3 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 11 | 18 | 15 | 16 | |
| Tax % | 28% | 13% | 31% | 35% | 49% | 6% | 17% | 8% | 13% | 15% | 6% | 39% | 29% | 29% | |
| Net Profit | 3 | 4 | 2 | 3 | 2 | 5 | 5 | 6 | 5 | 5 | 10 | 11 | 10 | 11 | |
| EPS in Rs | 1.49 | 1.70 | 0.95 | 1.43 | 1.11 | 2.21 | 2.06 | 2.62 | 2.10 | 2.04 | 4.61 | 4.95 | 4.62 | 5.08 | |
| Raw PDF | — |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202652.52%Promoter
Promoters52.52%0.34
FIIs12.13%0.81
DIIs11.37%0.05
Public23.98%1.11
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Sakar Healthcare | ₹1,179.80 | 72.74 | 2,625 | 0.00% | 10 | +120.13% | 73 | +38.36% | 12.42% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports8
Concall transcripts13
Credit ratings6
Announcements5
Analysts/Institutional Investor Meet/Con. Call Updates 14 Sep - Sakar Healthcare to hold analyst and investor plant visit on September 17-18, 2026.Analysts/Institutional Investor Meet/Con. Call Updates 14 Sep - Sakar Healthcare will host analyst and investor plant visits and management meetings on September 17-18, 2026.General Updates 1 Sep - Sakar received 14 oncology product approvals in EU, UK and Canada with 7 partners.Copy of Newspaper Publication 29 Aug - AGM on 22 September 2026; e-voting from 19-21 September; book closure 12-21 September.Shareholders meeting 27 Aug - Company submitted 22nd AGM notice and Annual Report 2025-26.